UNASSIGNED: The purpose of this study is to examine the studies on aripiprazole as a pharmacological treatment of delirium present in today\'s literature.
UNASSIGNED: We carried out systematic research of MedLine, PubMed, Cochrane, Embase, and ScienceDirect examining articles written between January 2002 and September 2023, including experimental studies published in peer-reviewed journals.
UNASSIGNED: The 6 final included studies examined a total of 130 patients, showing a delirium resolution in a 7-day span of 73.8% of patients treated with aripiprazole.
UNASSIGNED: Considering the limited data currently available, we can assert that aripiprazole is at least as efficient as haloperidol, the true point is that it has a far better tolerability and safety profile. Nonetheless, further studies are necessary to provide more compelling data, together with a more precise indication regarding minimum efficient dose, as the main limitations of our review are the very small sample size, the small percentage of subjects with preexisting dementia, and the fact that most studies used scales with low specificity for the examined condition.
■本研究的目的是考察目前文献中关于阿立哌唑作为谵妄药物治疗的研究。
■我们对MedLine进行了系统的研究,PubMed,科克伦,Embase,和ScienceDirect审查2002年1月至2023年9月之间撰写的文章,包括发表在同行评审期刊上的实验研究。
■6项最终纳入研究共检查了130名患者,在接受阿立哌唑治疗的患者中,73.8%的患者出现谵妄消退。
■考虑到当前可用的有限数据,我们可以断言阿立哌唑至少和氟哌啶醇一样有效,真正的观点是它具有更好的耐受性和安全性。尽管如此,需要进一步的研究来提供更有说服力的数据,以及关于最低有效剂量的更精确的指示,由于我们审查的主要限制是样本量非常小,一小部分先前存在痴呆症的受试者,以及大多数研究使用对所检查条件具有低特异性的量表的事实。